Zynerba Pharmaceuticals, Inc. (ZYNE) Comparison with companies in other sectors?

Zynerba Pharmaceuticals, Inc. has a share price of 53.94M. You can analyze Zynerba Pharmaceuticals, Inc. (ZYNE) competitors across different market sectors through stock heatmaps.

What are ZYNE's NET and operating margins?

Zynerba Pharmaceuticals, Inc. (ZYNE) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does ZYNE's earnings per share (EPS) trend reflect its financial momentum?

Zynerba Pharmaceuticals, Inc. (ZYNE) EPS is -0.79 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Zynerba Pharmaceuticals, Inc. is -1.65, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Zynerba Pharmaceuticals, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Zynerba Pharmaceuticals, Inc. like P/E which is -1.59, P/B which is 1.20, and PEG which is -0.02. Compare them with sector averages to evaluate if the stock is priced fairly.

Zynerba Pharmaceuticals, Inc.

ZYNE•NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

$1.30

$0.03(2.36%)

Fundamental Analysis of Zynerba Pharmaceuticals, Inc. (ZYNE)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.79

P/E Ratio

-1.65

ROE

-0.59%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$70.12M

Shares OutstandingTotal number of shares issued

$53.94M

Book Value/ShareNet worth per share

$1.08

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.79

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

-59.45%

ROAReturn on total assets

-62.72%

ROCEReturn on capital employed

-76.06%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.54

Cash/ShareCash and equivalents per share

$1.19

FCF YieldFree cash flow as percentage of market cap

-33.06%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ZYNEFinancial Ratios Analysis details for ZYNE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ZYNESector Benchmarking details for ZYNE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Zynerba Pharmaceuticals, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Zynerba Pharmaceuticals, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Zynerba Pharmaceuticals, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Zynerba Pharmaceuticals, Inc.

For Zynerba Pharmaceuticals, Inc., essential financial indicators include EPS -0.79, PE -1.65, and ROE -0.59. These key ratios reveal insights into Zynerba Pharmaceuticals, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Zynerba Pharmaceuticals, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Zynerba Pharmaceuticals, Inc.

Metrics like Net Margin - and ROA -62.72% shed light on how well Zynerba Pharmaceuticals, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Zynerba Pharmaceuticals, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Zynerba Pharmaceuticals, Inc.

Using ratios such as P/B Ratio 1.20 and PEG Ratio -0.02, investors can assess whether Zynerba Pharmaceuticals, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Zynerba Pharmaceuticals, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Zynerba Pharmaceuticals, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.007 and Cash Flow $-0.54, provide a snapshot of Zynerba Pharmaceuticals, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Zynerba Pharmaceuticals, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Zynerba Pharmaceuticals, Inc.

Investing in Zynerba Pharmaceuticals, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Zynerba Pharmaceuticals, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;